These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 35893281)
1. Successful Consolidation/Maintenance Therapy with Single Agent Ibrutinib for Primary CNS Lymphoma after Initial Induction Therapy. Du S; Bota D; Kong XT Neurol Int; 2022 Jun; 14(3):574-580. PubMed ID: 35893281 [TBL] [Abstract][Full Text] [Related]
2. Prolonged remission with ibrutinib maintenance therapy following radiation in a patient with relapsed primary CNS lymphoma. Du S; Fu DB; A Bota D; Kong XT CNS Oncol; 2024 Jun; 13(1):2345579. PubMed ID: 38722227 [TBL] [Abstract][Full Text] [Related]
3. A phase 2 study of ibrutinib maintenance following first-line high-dose methotrexate-based chemotherapy for elderly patients with primary central nervous system lymphoma. Bairey O; Taliansky A; Glik A; Amiel A; Yust-Katz S; Gurion R; Zektser M; Porges T; Sarid N; Horowitz NA; Shina TT; Lebel E; Cohen A; Geiger KR; Raanani P; Wolach O; Siegal T Cancer; 2023 Dec; 129(24):3905-3914. PubMed ID: 37572086 [TBL] [Abstract][Full Text] [Related]
4. Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma-evaluation of anti-tumor efficacy and brain distribution. Yu H; Kong H; Li C; Dong X; Wu Y; Zhuang Y; Han S; Lei T; Yang H Transl Cancer Res; 2021 May; 10(5):1975-1983. PubMed ID: 35116520 [TBL] [Abstract][Full Text] [Related]
5. Primary central nervous system lymphoma in older adults and the rationale for maintenance strategies: a narrative review. Tsang M; Rubenstein JL; Pulczynski EJ Ann Lymphoma; 2021 Sep; 5():. PubMed ID: 35106521 [TBL] [Abstract][Full Text] [Related]
6. High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials. Yu J; Du H; Ye X; Zhang L; Xiao H Sci Rep; 2021 Jan; 11(1):2125. PubMed ID: 33483528 [TBL] [Abstract][Full Text] [Related]
7. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. Grommes C; Tang SS; Wolfe J; Kaley TJ; Daras M; Pentsova EI; Piotrowski AF; Stone J; Lin A; Nolan CP; Manne M; Codega P; Campos C; Viale A; Thomas AA; Berger MF; Hatzoglou V; Reiner AS; Panageas KS; DeAngelis LM; Mellinghoff IK Blood; 2019 Jan; 133(5):436-445. PubMed ID: 30567753 [TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use. Chen F; Pang D; Guo H; Ou Q; Wu X; Jiang X; Wei X; Liu S; Huang L; Liang Z; Zhou D; Li W Cancer Med; 2020 Nov; 9(22):8676-8684. PubMed ID: 33068336 [TBL] [Abstract][Full Text] [Related]
9. Treatment of Primary Central Nervous System Lymphoma in Immunocompetent Patients. Garcilazo-Reyes Y; Alentorn A; Duran-Pena A; Hoang-Xuan K; Houillier C Curr Treat Options Neurol; 2019 Jul; 21(8):39. PubMed ID: 31324993 [TBL] [Abstract][Full Text] [Related]
10. [Perspectives on Precision Medicine in Primary Central Nervous System Lymphoma]. Sasaki N; Nagane M No Shinkei Geka; 2022 Jan; 50(1):51-60. PubMed ID: 35169086 [TBL] [Abstract][Full Text] [Related]
11. Case report: Successful treatment of a patient with relapsed/refractory primary central nervous system lymphoma with thiotepa-based induction, autologous stem cell transplantation and maintenance. Wang L; Fan Y; Chen B; Zhang J; Yang L; Qiu X; Jiang H; Li J; Xiao X; Huang L; Xu Y Front Oncol; 2023; 13():1333761. PubMed ID: 38348121 [TBL] [Abstract][Full Text] [Related]
12. Temozolomide as a Single Agent Maintenance Therapy in Elderly Patients With Primary CNS Lymphoma. Faivre G; Butler MJ; Le I; Brenner A Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):665-669. PubMed ID: 31351990 [TBL] [Abstract][Full Text] [Related]
13. [Clinical Efficacy of High Dose Methotrexate, Temozolomide and Rituximab in the Treatment of Patients with Primary Central Nervous System Lymphoma]. Pang DW; Chen FL; Guo HG; Jiang XM; Wei XJ; Liu SC; Huang L; Liang ZL; Li WY Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1175-1180. PubMed ID: 34362499 [TBL] [Abstract][Full Text] [Related]
14. Challenges in the Treatment of Newly Diagnosed and Recurrent Primary Central Nervous System Lymphoma. Holdhoff M; Mrugala MM; Grommes C; Kaley TJ; Swinnen LJ; Perez-Heydrich C; Nayak L J Natl Compr Canc Netw; 2020 Nov; 18(11):1571-1578. PubMed ID: 33152700 [TBL] [Abstract][Full Text] [Related]
15. [Treatment of Primary Central Nervous System Lymphoma: Standard Treatments According to the Japanese 2019 Guideline and Novel Treatments]. Sasaki N; Nagane M Brain Nerve; 2021 Oct; 73(10):1107-1114. PubMed ID: 34615748 [TBL] [Abstract][Full Text] [Related]
16. Systemic Approach to Recurrent Primary CNS Lymphoma: Perspective on Current and Emerging Treatment Strategies. Holdhoff M; Wagner-Johnston N; Roschewski M Onco Targets Ther; 2020; 13():8323-8335. PubMed ID: 32903865 [TBL] [Abstract][Full Text] [Related]
17. Non-Myeloablative Chemotherapy as Consolidation Strategy After High-Dose Methotrexate-Based Chemoimmunotherapy in Patients With Primary CNS Lymphoma: A Retrospective Single Center Study in China. Sun X; Wu Y; Xing R; Bai X; Qian J; Zhu H; Cui Q; Chen Y; Liu Q; Lai W; Li J; Wang Y; Sun S; Gao C; Ji N; Liu Y Front Oncol; 2022; 12():792274. PubMed ID: 35280789 [TBL] [Abstract][Full Text] [Related]
19. Zanubrutinib in the Maintenance Treatment of Elderly People with Primary Central Nervous System Lymphoma: A Report of 2 Cases. Liu Y; Sun J; Tuo K Case Rep Oncol; 2023; 16(1):227-233. PubMed ID: 37069896 [TBL] [Abstract][Full Text] [Related]
20. Challenges and opportunities in primary CNS lymphoma: A systematic review. Kerbauy MN; Moraes FY; Lok BH; Ma J; Kerbauy LN; Spratt DE; Santos FP; Perini GF; Berlin A; Chung C; Hamerschlak N; Yahalom J Radiother Oncol; 2017 Mar; 122(3):352-361. PubMed ID: 28104300 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]